Sentinel node biopsy in clinical stage I testicular cancer enables early detection of occult metastatic disease.

Blok, Joost M; Kerst, J Martijn; Vegt, Erik; Brouwer, Oscar R; Meijer, Richard P; Bosch, J L H Ruud; Bex, Axel; van der Poel, Henk G et al. · BJU Int · 2019

case_series · Level IV

Where this comes from

Abstract

To report the long-term results of the sentinel node (SN) approach in patients with clinical stage I testicular tumours in our facility. We conducted an analysis of 27 consecutive patients suspected of clinical stage I testicular germ cell tumour (TGCT) and treated with an SN procedure at our tertiary referral centre. SNs were identified using lymphoscintigraphy with or without single-photo-emission computed tomography with CT (SPECT/CT). Patients underwent laparoscopic retroperitoneal SN excision with inguinal orchiectomy. Patients with a tumour-positive SN underwent adjuvant treatment. Follow-up was conducted according to then-current guidelines. In two patients, no SNs were visualized on scintigraphy. In the remaining 25 patients, a median (range) of 3 (1-4) SNs per patient were removed. Two patients showed no malignancy on histopathological examination of the testis. Of the 23 patients diagnosed with TGCT (16 seminomas, seven non-seminomas), three (13.0%) had occult metastatic disease. All 23 patients were without evidence of disease at a median (range) follow-up of 63.9 (29.0-143.4) months. The SN procedure allows early identification of patients with occult metastatic disease in clinical stage I TGCT, enabling early treatment.

Medical subject headings